BioSpace News Archive

Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced that Walter E Kaufmann, M.D. has been promoted to Chief Scientific Officer and Edward R Hammond, M.D., M.P.H., PhD, has been appointed Chief Medical Officer.

2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach.

AngioDynamics, Inc. today announced financial results for the second quarter of fiscal year 2022, which ended November 30, 2021.

Xilio Therapeutics, Inc. today announced the appointment of Yuan Xu, Ph.D., to its board of directors.

Humacyte, Inc. (Nasdaq: HUMA), today announced that results from the first series of compassionate use cases of Humacyte’s Human Acellular VesselTM (HAV) will be presented at the 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society (VESS) in Snowmass, Colo. at 7:56 a.m. MST on January 28, 2022.

KemPharm, Inc. announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.

Soligenix, Inc. announced that the Company will deliver a corporate presentation at the upcoming virtual investor conferences below.

Apnimed to Present at the 40th Annual JP Morgan Healthcare Conference.

Alnylam Pharmaceuticals, Inc. today announced a collaboration with Novartis to leverage Alnylam’s proven, proprietary siRNA technology.